EDDC-2214

N/A

Report date: 2022/01/14 12:35:52
NME

Base Information

Drug NameEDDC-2214
Drug Alias NameEDDC-2214
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExperimental Drug Development Centre
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (Suzhou) IncYunding Xinyao Co LtdExperimental Drug Development Centre
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A